Expert Interviews

Mark T. Fleming, MD – Ushering Early-Phase Prostate Cancer Therapies from Development to Everyday Treatment
Dr. Fleming is a genitourinary medical oncologist at Virginia Oncology Associates, where he coordinates the Genitourinary Research Program and leads the Phase 1 Program. Additionally, he is the medical director of Sarah Cannon Research Institute’s Genitourinary Committee. Dr. Fleming is considered a leading world expert in novel therapy research in genitourinary oncology and is credited with helping develop and investigate the oral androgen-receptor-signaling inhibitor enzalutamide in metastatic castration-resistant prostate cancer. ...
Advertisement
Advertisement

Featured Knowledge Hubs

Prostate Cancer
Prostate Cancer
Advertisement
Advertisement